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Abstract Antibodies against prothrombin are detected by
enzyme immunoassays (EIA) in sera of patients with
antiphospholipid syndrome (APS). However, there are
two methods for antiprothrombin EIA; one that uses
high binding plates (aPT-A), and another that utilizes
phosphatidylserine bound plates (aPS/PT). We aimed to
evaluate and compare aPT-A and aPS/PT in a clinical set-
ting. We performed EIA for anti-PT, anti-PS/PT, IgG, and
IgM anticardiolipin antibodies (aCL), and IgG β2-glycopro-
tein I-dependent aCL (aβ2GPI/CL) with serum samples
from 139 systemic lupus erythematosus (SLE) patients (16
with history of at least one thrombotic episode) and 148
controls. We observed that: (1) although titers of anti-PT
and anti-PS/PT were signiﬁcantly related with each other (P
< 0.0001, ρ = 0.548), titer of anti-PT and anti-PS/PT differed
greatly in some samples; (2) odds ratio and 95% conﬁdence
interval for each assay was 3.556 (1.221–10.355) for aPT-A,
4.591 (1.555–15.560) for aPS/PT, 4.204 (1.250–14.148) for
IgG aCL, 1.809 (0.354–9.232) for IgM aCL, and 7.246
(2.391–21.966) for aβ2GPI/CL. We conclude that, while all
EIA performed in this study except IgM aCL are of poten-
tial value in assessing the risk of thrombosis, aPS/PT and
aβ2GPI/CL seemed to be highly valuable in clinical prac-
tice, and that autoantibodies detected by anti-PT and anti-
PS/PT are not completely identical.
Key words Antiphospholipid syndrome · Antiprothrombin
antibody · Enzyme immunoassay · Systemic lupus erythe-
matosus (SLE)
A. Tsutsumi (*) · T. Hayashi · Y. Chino · M. Mamura · D. Goto ·
I. Matsumoto · S. Ito · T. Sumida
Division of Clinical Immunology, Major of Advanced Biomedical
Applications, Graduate School of Comprehensive Human Sciences,
University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
Tel./Fax +81-29-853-3186
e-mail: atsutsum@md.tsukuba.ac.jp
Introduction
Antiphospholipid antibodies (aPL) are a group of heteroge-
neous autoantibodies against a variety of phospholipid bind-
ing proteins. Detection of aPL by radioimmunoassay was
ﬁrst reported by Harris et al.,
1  and detection of
anticardiolipin antibody (aCL) by enzyme immunoassay
(EIA) was reported by Koike et al. in 1984.
2 The develop-
ment of these relatively simple methods enabled researchers
to perform a number of clinical studies, and the clinical entity
antiphospholipid syndrome (APS), proposed by Hughes et
al., was established during the 1980s. This syndrome is char-
acterized by the presence of aPL and occurrence of throm-
botic episodes and/or intrauterine fetal deaths.
Methods currently used for detecting aPL can be divided
to two categories: lupus anticoagulant (LAC) tests and
EIA. Enzyme immunoassays are frequently used for detec-
tion of aPL, due to their relative simplicity and reliability. A
standardized aCL EIA, described by Harris et al.,
3 is widely
used for detection of aPL and the diagnosis of APS. How-
ever, during the last decade it has become evident that
anticardiolipin antibodies are in fact autoantibodies against
phospholipid binding proteins. The ﬁrst such protein de-
scribed is β2-glycoprotein I (β2GPI). It is suggested that
β2GPI undergo a conformational change upon binding to
negatively charged phospholipids, which in turn causes
exposure of neoepitopes that are detected by aCL. Alterna-
tively, the density of β2GPI may be important for recogni-
tion by aCL, and appropriate β2GPI density is achieved by
binding to negatively charged phospholipids. Enzyme im-
munoassay for detection of β2GPI dependent aCL is re-
ported to be of value in clinical practice
4–6 and is included in
the proposed Sapporo criteria for classiﬁcation of APS.
7
Enzyme immunoassays using β2GPI directly coated on oxi-
dized plates (high binding plates) are also reported to be
useful.
8–12
Prothrombin is another important autoantigen recog-
nized by aPL. Shortly after the description of β2GPI as the
aCL “cofactor,”
13–15 Bevers et al.
16 reported that the IgG
with LAC activity recognizes a complex of phospholipids159
and prothrombin. Thereafter, a number of studies with re-
gard to the relationship between thrombotic events and
presence of antiprothrombin antibodies as measured by
EIA have been reported, with conﬂicting conclusions.
17
Interestingly, two methods for antiprothrombin antibody
detection have been suggested, similar to the case for anti-
β2GPI detection. One is an assay that utilizes prothrombin
coated directly onto high binding plates (in this paper re-
ferred to as aPT-A), and the other is an assay that detects
antibodies bound to prothrombin on phosphatidylserine-
coated plates (in this paper referred to as aPS/PT). The
large differences in the results among the reports that stud-
ied the relevance of antiprothrombin EIA may partly be
due to the methods of the EIA employed in individual
studies. However, very few studies have directly compared
the aPT-A and the aPS/PT assays.
18,19
In this study, we aimed to compare these two antipro-
thrombin EIA, along with other aPL EIA (IgG and IgM
aCL, IgG aβ2GPI/CL) and LAC, for their values in assess-
ing the risk of thrombosis in patients with systemic lupus
erythematosus (SLE). In particular, for all EIA, we mea-
sured the values of each antibody in our own healthy
controls and have set the cutoff points anew to enable com-
parison of these assays from a same viewpoint.
Material and methods
Subjects and samples
Serum and plasma samples were taken from 139 SLE pa-
tients followed at University of Tsukuba Hospital, Tsukuba,
Ibaraki, Japan. All SLE patients fulﬁlled the 1987 ACR
criteria
20,21  for the classiﬁcation of SLE. Among these
patients, 16 had one or more documented episodes of
thrombosis (11 with arterial thromboses, 8 with venous
thromboses, 3 with both arterial and venous thromboses).
Mean follow-up period at the time of blood sampling was
9.95 ± 8.23 (mean ± SD) years; 9.00 ± 9.49 years for patients
with history of thromboses, and 10.07 ± 8.09 years for pa-
tients without history of thromboses. Warfarin was started
in 11 patients after diagnosis of thrombosis, and in a mean
follow-up of 2.64 ±  2.87 years, no additional thrombotic
episodes were noticed. Samples from 148 healthy volun-
teers, with no apparent history of thrombosis or autoim-
mune diseases, served as controls. Written informed
consent was obtained from all subjects of this study, and the
study was approved by the ethics committee of the Univer-
sity of Tsukuba.
Antiphospholipid antibody assays
Antiprothrombin antibodies measurement using high
binding plates
Nunc Maxisorp plates (Nalge Nunc, Rochester, NY) were
used. One hundred microliters per well (µl/well) of human
prothrombin (Haematologica Technologies, Essex Junc-
tion, VT, USA) in carbonate buffer, pH 9.6, at a concentra-
tion of 10µg/ml was coated onto wells at room temperature
overnight. After blocking by 1% bovine serum albumin
(BSA) in Tris-buffered saline including 5mM calcium
(TBS), 100µl/well of sample sera diluted 1:200 in TBS with
1% BSA and 0.5% Tween-20 (TBS/Tw) were added to the
wells, and the plates were incubated for 2h at room tem-
perature. After washing with TBS/Tw, alkaline phosphatase
labeled goat antihuman IgG antibody (American Qualex,
SanClemente, CA, USA) diluted 1:2500 in TBS/Tw were
added to the wells, and the plates were incubated for 1h at
room temperature. After further washing, substrate was
added and the optical density was measured at 405nM by an
autoreader. A standard curve was always generated using a
standard serum, the antibody concentration in which desig-
nated as 100 units/ml.
Anti-phosphatidylserine/prothrombin antibodies
For the measurement of aPS/PT, a commercially available
EIA kit (Medical and Biological Laboratories, Nagoya, Ja-
pan)
22 was used. The kit detects aPS/PT in the presence of
calcium and follows, in principle, the method described by
Atsumi et al.
18  The wells of the plates are coated with
phosphatidylserine/human prothrombin by the supplier.
Sample sera were diluted at 1:100 with the supplied dilution
buffer, and 100µl of each sample were added to the wells.
The plates were incubated for 1h at room temperature, and
bound antibodies were detected by a peroxidase labeled
goat anti-human IgG antibody.
Anticardiolipin antibodies
Anticardiolipin antibodies were measured according to the
methods described by Harris et al.,
3 using a Mesacup cardio-
lipin kit (Medical and Biological Laboratories) and a
Mesacup cardiolipin IgM kit (Medical and Biological
Laboratories).
Anticardiolipin/β2-glycoprotein I antibodies
Serum aβ2GPI/CL were measured using anticardiolipin/β2-
glycoprotein I antibody enzyme-linked immunosorbent as-
say (ELISA) kit (Yamasa Shoyu, Chosi, Japan). The kit is
supplied with plates coated with cardiolipin. The wells were
ﬁrst incubated with sample dilution buffer with or without
β2GPI. Sample sera were diluted at 1:101 with the supplied
dilution buffer, and 50µl /well of each sample was added to
both the aβ2GPI added and non-added wells. Plates were
incubated for 30min at room temperature. Bound antibod-
ies were detected by a peroxidase labeled anti-human IgG
antibody. Samples were considered positive for aβ2GPI/CL
when the values obtained from the β2GPI added wells ex-
ceeded the cutoff point, and were above the values obtained
from β2GPI non-added wells.
Determination of cutoff levels for enzyme immunoassays
Although the cutoff levels for commercially available EIA
tests are determined by the suppliers, the deﬁnition of a160
cutoff level differs among assays, and different control
populations are used for the determination of each cutoff
level in an assay. Therefore, to compare various assays from
a same viewpoint, the cutoff levels for all EIA were deter-
mined anew. For all assays, the cutoff levels were set at
mean + 2SD of our control samples.
Lupus anticoagulant assay
Lupus anticoagulant assay was performed using an LA test
kit (Gradipore, North Ryde, Australia), which is based on a
simpliﬁed dilute Russel viper venom time described by
Exner et al.
23 Ratios equal to or larger than 1.3 were consid-
ered positive for LA.
Statistical analyses
Relationships between the levels of EIA were compared by
Spearman’s rank correlation test. Differences in titer of any
aPL measured by EIA between SLE patients with history of
thromboses and patients without such history were com-
pared by the Mann–Whitney U-test. Positivity for any aPL
assay and having histories of thromboses were compared by
Fisher’s exact test. P values equal to or less than 0.05 were
considered as statistically signiﬁcant.
Results
Cutoff levels of enzyme immunoassays
The cutoff levels of all ﬁve EIA performed in this study
were determined anew from the same 148 sample sera. The
cutoff levels for aPT-A, aPS/PT, aβ2GPI/CL, IgG aCL, and
IgM aCL assays were 17.95, 17.83, 0.57, 15.43, and 5.69,
respectively. Values above these cutoff levels were consid-
ered positive for a given assay.
Titer of various antiphospholipid antibodies in SLE
patients with or without history of thrombotic episodes
The levels of each EIA were compared between patients
with history of thrombosis and those without thrombosis. In
all assays, patients with history of thrombosis had signiﬁ-
cantly higher values compared to those without such history
(Fig. 1). The differences observed between patients with or
without thrombotic episodes seemed especially large in
aPS/PT, although it is difﬁcult to compare the assays in this
way since the “unit” in each assay was deﬁned indepen-
dently among each other.
Results of antiprothrombin antibodies detected using high
binding plates and those of antiphosphatidylserine/
prothromnbin antibodies are signiﬁcantly correlated with
each other
It has been suggested that the values obtained by aPT-A
and aPS/PT assays do not necessarily correlate with each
other.
18  We compared the values of aPT-A and aPS/PT
among sera from SLE patients. These values were signiﬁ-
cantly correlated with each other (ρ = 0.514, P < 0.0001 by
Spearman’s rank correlation), compared to relationships
among other aPL such as between aPT-A and aβ2GPI/CL
(Fig. 2 and results not shown). However, some sera had high
value for only one or the other of those assays.
Positivity of antiphosphatidylserine/prothrombin antibody
and/or antiprothrombin antibody is correlated with having
histories of thrombotic episodes
Positivity for aPS/PT was signiﬁcantly related with having
history of thrombosis (Tables 1 and 2). aPT-A positivity was
also signiﬁcantly related with history of thrombosis.
Positivity of β2GPI-dependent aCL and/or lupus
anticoagulant is signiﬁcantly correlated with having
histories of thrombotic events
When the cutoff level of aβ2GPI/CL was set at 3.5 units as
recommended by the supplier, 17 were positive, among
whom 5 had history of thrombotic episodes (P = 0.0282 by
Fisher’s exact test). When the cutoff level was adjusted
using data from our own healthy controls, a more signiﬁcant
relationship was observed (Tables 1 and 2). The OD values
equivalent to 0.6 units were around 0.060–0.070 in the pres-
ence of β2GPI, and around 0.015–0.040 in the absence of
β2GPI (not shown). Being positive for LAC was also
signiﬁcantly associated with history of thrombosis.
Fig. 1. Values of antiphospholipid antibodies as measured by enzyme
immunoassays in patients with systemic lupus erythematosus. One
hundred and thirty-nine patients with systemic lupus erythematosus
were divided into two groups (patients with or without history of
thrombosis) and were applied to various antiphospholipid antibody
enzyme immunoassays. Values are in arbitrary units determined inde-
pendently for each enzyme immunoassay. Numbers above indicate P
values calculated by Mann–Whitney U-test aPT-A, antiprothrombin
antibody measured using high binding plates; aPS/PT,
antiphosphatidylserine/prothrombin antibody; aCL, anticardiolipin
antibody;  aβ2GPI/CL,  β2 glycoprotein I-dependent anticardiolipin
antibody
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aCL, 8 had history of one or more thrombosis episodes,
yielding a P  value of 0.0091 as calculated by Fisher’s
exact test. No association between IgM aCL positivity
and history of thrombosis was seen, regardless of whether
the cutoff point was set at the values set by the manufac-
turer (1 of 7 positive patients with history of thrombosis, P
= 0.5837 by Fisher’s exact test), or that set by ourselves
(Table 1).
Table 1. Relationship between positivity of antiphospholipid assays and history of thrombosis
Thrombosis Total Odds ratio 95% CI P value
Yes No
aPT-A Positive 8 27 35 3.556 1.221–10.355 0.0278
Negative 8 96 104
aPS/PT Positive 8 22 30 4.591 1.555–15.560 0.0072
Negative 8 101 109
aβ2GPI/CL Positive 10 23 33 7.246 2.391–21.966 0.0005
Negative 6 100 106
IgG aCL Positive 5 12 17 4.204 1.250–14.148 0.0282
Negative 11 111 122
IgM aCL Positive 2 9 11 1.809 0.354–9.232 0.6158
Negative 14 114 128
LAC Positive 7 9 16 9.852 2.972–32.657 0.0004
Negative 9 114 123
aPT-A, antiprothrombin antibody measured using high binding plates; aPS/PT, antiphosphatidylserine/prothrombin antibody; aβ2GPI/CL, β2-
glycoprotein I dependent anticardiolipin antibody; aCL, anticardiolipin antibody; LAC, lupus anticoagulant
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Fig. 2a,b. Relationship between values of antiprothrombin antibody
and antiphosphatidylserine/prothrombin antibody in sera of patients
with systemic lupus erythematosus. The values of antiprothrombin
antibody and antiphosphatidylserine/prothrombin antibody in patients
with systemic lupus erythematosus were compared. For comparison,
the values of antiprothrombin antibody and β2-glycoprotein I-depen-
dent anticardiolipin antibody were also compared. a Antiprothrombin
antibody and antiphosphatidylserine/prothrombin antibody. ρ = 0.514,
P < 0.0001 by Spearman’s rank correlation. b Antiprothrombin anti-
body and β2 glycoprotein I-dependent anticardiolipin antibody. ρ =
0.086,  P  =  0.3103 by Spearman’s rank correlation. aPT-A, antipro-
thrombin antibody measured using high binding plates; aPS/PT,
antiphosphatidylserine/prothrombin antibody; aβ2GPI/CL, β2 glyco-
protein I-dependent anticardiolipin antibody
Relationships between conventional aCL assays, lupus
anticoagulant assay, and history of thrombosis
The relationship between positivity of IgG aCL and history
of thrombosis was statistically signiﬁcant when the cutoff
value was set at mean + 2SD of our control samples (Table
1). When the cutoff level was set at 10 units, originally set by
the manufacturer, among the 31 patients positive for IgG162
were positive for at least one of the antiphospholipid anti-
body assays performed. While a combination of IgG aCL
and LAC enabled us to judge 8 patients as positive for aPL,
a combination of aPS/PT and aβ2GPI/CL indicated 10 as
positive for aPL.
Positivity of antiphospholipid antibodies among SLE
patients with history of pregnancy
Among 69 SLE patients who had history of at least one
pregnancy, only 3 had a history of recurrent fetal losses.
Among patients with history of at least one pregnancy, the
number of patients positive for a given antibody and with
history of fetal loss, the number of patients of patients posi-
tive for the antibody, P values calculated by Fisher’s exact
test were 2/16, 0.1321 for aPT-A, 1/17, >0.9999 for aPS/PT,
0/5, >0.9999 for IgG aCL, 0/4, >0.9999 for IgM aCL, 2/13,
0.0888 for aβ2GPI/CL, and 1/6, 0.2421 for LAC, respec-
tively. For aβ2GPI/CL, when the cutoff value was set at 3.5
units, as determined by the supplier, the numbers became 2/
Table 2. Sensitivity, speciﬁcity, and positive predictive values of
antiphospholipid assays for history of thromboses in patients with
systemic lupus erythematosus
Sensitivity Speciﬁcity Positive predictive value
aPT-A 0.500 0.775 0.229
aPS/PT 0.500 0.821 0.267
aβ2GPI/CL 0.625 0.813 0.303
IgG aCL 0.313 0.902 0.294
IgM aCL 0.125 0.927 0.182
LAC 0.438 0.927 0.438
aPT-A, antiprothrombin antibody measured using high binding plates;
aPS/PT, antiphosphatidylserine/prothrombin antibody; aβ2GPI/CL,
β2-glycoprotein I dependent anticardiolipin antibody; aCL,
anticardiolipin antibody; LAC, lupus anticoagulant
Table 3. Positivity of antiphospholipid assays in patients with history of thrombosis
Patient Thrombosis aPT-A aPS/PT aβ2GPI/CL IgG aCL IgM aCL LAC
1A −− − − − −
2A −− − − − −
3A ++ + − − −
4V +− + − − +
5V −− − − − +
6 A,V ++ + − − +
7A +− − + − −
8A ++ + + − +
9A ++ + + − +
10 A −− − − − −
11 V +− − − − −
12 V −+ + + + +
13 A,V −+ + − + −
14 A −− + − − −
15 V −+ + − − −
16 A,V ++ + + − +
A, with history of arterial thromboses; V, with history of venous thromboses; aPT-A, antipro-
thrombin antibody measured using high binding plates; aPS/PT, antiphosphatidylserine/
prothrombin antibody; aβ2GPI/CL, β2-glycoprotein I-dependent anticardiolipin antibody; aCL,
anticardiolipin antibody; LAC, lupus anticoagulant
Summary of thrombotic history: 1. Cerebral infarction (CI), occurring before diagnosis of sys-
temic lupus erythematosus (SLE). No additional events with low-dose aspirin. 2. Left atrial
thrombosis, found at the time of diagnosis of SLE. No recurrence with warfarin plus low-dose
aspirin. 3. CI, occurring 21 years after diagnosis of SLE, while on low-dose aspirin. No further
events after addition of warfarin. 4. Deep vein thrombosis (DVT) and pulmonary embolism (PE),
occurring 3 years after diagnosis of SLE, while on low-dose aspirin. No further events after
addition of warfarin. 5. PE found 2 years after diagnosis of SLE, while without any anticoagula-
tion. Dipyridamole was added. Warfarin added 10 years after diagnosis of SLE to delay the
progression of pulmonary hypertension. 6. Old lung infarction noticed 22 years after diagnosis of
SLE, while under low-dose aspirin. No further episodes. 7. CI occurred 15 years before occur-
rence of SLE. 8. DVT occurred in the ﬁrst year after diagnosis of SLE while under low-dose
aspirin. Warfarin was added and no further episodes noticed. 9. PE, found 17 years after diagnosis
of SLE while drug free. No episodes after addition of warfarin. 10. CI, occurring before diagnosis
of SLE. 11. DVT, occurring 4 years after diagnosis of SLE. No recurrence after addition of
warfarin. 12. DVT, found at the time of diagnosis of SLE. No recurrence after addition of warfarin
and low-dose aspirin. 13. DVT, PE, both found at the time of diagnosis of SLE. No recurrence
after addition of warfarin and low-dose aspirin. 14. Myocardial infarction occurring 24 years after
diagnosis of SLE. CI found by further examination. No recurrence after low-dose aspirin and
ticlopidine hydrochloride. 15. DVT, occurring 5 years after diagnosis of SLE while under no
anticoagulation. No recurrence after addition of warfarin and low-dose aspirin. 16. CI, PE, both
found at the time of diagnosis of SLE. No recurrence after addition of warfarin
Positivity of antiphospholipid antibodies among SLE
patients with history of thrombosis
The 16 SLE patients with history of thrombosis were as-
sessed for their aPL positivity (Table 3). Thirteen patients163
8 and 0.0337. Other assays did not yield signiﬁcant P values.
However, the number of patients with history of recurrent
fetal losses was too small to allow us to draw a reliable
conclusion.
Discussion
Previous studies suggested that aPT-A and aPS/PT assays
detect signiﬁcantly different populations of autoantibodies
and the results of the two assays may not correlate with each
other. We applied the two assays to the same samples con-
sisting of SLE patients and healthy individuals to assess the
differences between the two assays. Results show that both
assays, aPS/PT in particular, are of potential value in assess-
ing the risk of thrombosis in SLE patients.
Very recently, Bertolaccini et al.
19  also compared the
results of aPT-A and aPS/PT in their cohort of 212 SLE
patients. In their study they also found a signiﬁcant relation-
ship between the results of aPT-A and aPT/PS. Similar to
our study, they also noted the presence of a number of
patients with discrepant results. Thus, along with the results
of our study, it is conceivable that aPT-A and aPT/PS recog-
nize an overlapping, but not identical, population of auto-
antibodies. In their study, Bertolaccini et al. found a slightly
stronger relationship between positivity of IgG aPS/PS and
a history of thromboses than IgG aPT-A positivity and a
history of thromboses. However, they have not documented
how the aPS/PT-positive and aPT-A-positive patients over-
lap, when the presence of thrombotic history of thrombosis
was put into consideration. In our study, between 8 aPT-A-
positive SLE patients with a history of thrombosis and 8
aPS/PT-positive patients with a history of thrombosis, only
5 overlapped. These results could imply that performing
both aPT-A and aPS/PT assays, if possible, or developing a
new method that would enable detection of both popula-
tions of autoantibodies would be desirable for more sensi-
tive detection of clinically relevant antiprothrombin
antibodies. The reason why aPT-A and aPS/PT assays rec-
ognize overlapping, but not identical, populations of auto-
antibodies is not clear, but a most reasonable explanation
would be that the nature of conformational changes intro-
duced to prothrombin is different between when prothrom-
bin is bound to high binding plates and when it is bound to
phosphatidylserine bound plates. It is possible that the
conformational changes introduced when bound to
phosphatidylserine-coated plates is more similar to the
changes introduced in vivo, and this may account for the
higher clinical relevance of aPS/PT assay than that of aPT-
A assay observed in our study.
Assay for aβ2GPI/CL has become increasingly popular
in the clinical management of SLE in Japan. The assay has
been approved by the Ministry of Science Health and
Welfare of Japan as a tool for diagnosis of APS. As seen in
Table 1, positivity for this antibody was strongly correlated
with histories of thrombosis, suggesting its value in a clinical
setting. However, the cutoff value of aβ2GPI/CL in this
study was set at 0.57 units, different from 3.5 units recom-
mended by the manufacturer of the assay kit. In addition,
the OD values at 0.6 units were around 0.060 in the assay we
used. Thus, while setting the cutoff value at this level does
give us a better P value, implying the validity of the assay,
reﬁnement of the assay would be necessary to more accu-
rately measure low-titer aβ2GPI/CL. By standardizing the
methodology and appropriately setting the cutoff levels,
aβ2GPI/CL could become a more widely used measure for
the diagnosis of APS. Efforts to standardize this assay are
necessary. Previously, we have suggested
24 that aβ2GPI/CL
assays may be suitable to be included in the 1987 ACR
criteria,
20,21 which currently includes only LAC and conven-
tional aCL assays as means of aPL detection. Results pre-
sented in this study imply that aβ2GPI/CL EIA has similar
or superior value for the detection of aPL as IgG aCL. We
believe that inclusion of aβ2GPI/CL in the ACR criteria for
SLE may be beneﬁcial.
Currently, the Sapporo criteria, proposed in 1999, are
widely used for the diagnosis of APS.
7 In the Sapporo crite-
ria, for the detection of aPL, aCL, aβ2GPI/aCL, and LAC
assays are recommended. However, studies reported there-
after have suggested the values of antiprothrombin assays in
the diagnosis of APS. We wished to determine the values of
aPT-A and aPS/PT in a clinical setting and in particular,
wanted to determine whether routine measurement of
these antibodies would aid in the diagnosis of APS. For this
purpose, we decided to set the cutoff level of each EIA
anew, to evaluate each assay from the same viewpoint.
Among our 16 SLE patients with history of thrombosis, 8
were judged positive for aPL by the combination of IgG
aCL and LAC. Addition of aβ2GPI/aCL raised the number
of patients positive for aPL to 12, while addition of either
aPT-A or aPS/PT raised the number to 11. A combination
of aβ2GPI/aCL and aPS/PT judged 10 patients as positive
for aPL, and a combination of aPT-A, aPS/PT, and aβ2GPI/
aCL judged 12 as aPL-positive (Table 3). In our SLE pa-
tients, among the patients with history of thrombosis, all but
one of those positive for LAC were positive for at least
either aPS/PT or aβ2GPI/aCL. These results are quite rea-
sonable since a large part, if not the majority, of LAC
activity is β2GPI or prothrombin dependent. Reﬁnement of
these assays may show that these assays should have a posi-
tion in the diagnostic criteria of APS, and that they have the
potential to substitute LAC assays in the future. Although
the clinical signiﬁcance of LAC assays is well established,
carefully collected and preserved plasma needs to be used,
the methods are tedious and are still not completely
standardized.
By directly comparing aPS/PT and aPT-A assays along
with other aPL assays, using the same samples and the same
criteria to set cutoff levels, our current study indicated that
aPS/PT and aβ2GPI/aCL assays have more clinical rel-
evance than the aPT-A assay. However, aPT-A assay
seemed to be detecting a spectrum of autoantibodies not
detected by aPS/PT, and we believe that it is premature to
dismiss the assay as clinically meaningless.
In conclusion, we have shown the heterogeneity of
autoantibodies detected by aPT-A or aPS/PT assays, but
have also shown that these EIAs may be valuable in the164
diagnosis of APS. Although interlaboratory studies and
standardization of the assays are necessary, we believe that
these assays may have the potential to be included in the
future diagnostic criteria for APS and SLE.
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